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Pulmonary Kaposi’s sarcoma is a rare condition. Its diagnosis may be tricky due to its similarities 
in clinical and radiological features with pulmonary opportunistic infections as well as other lung 
lesions. Treatment for Kaposi’s sarcoma include radiotherapy, chemotherapy and/or 
immunotherapy whereby lung Kaposi’s sarcoma respond well to chemotherapy. An 
immunocompetent 68-year-old man was admitted with clinical, radiological and bronchoscopic 
features of bronchogenic carcinoma. However, the histological result revealed Kaposi’s sarcoma of 
the lung. The patient was treated with radiotherapy and recovered well from his symptoms. Six 




Kaposi’s sarcoma was first described by Moritz 
Kaposi in 1872 as a multifocal 
angioproliferative lesions (1,2). However, 
Goedert et al in 2002 described Kaposi’s 
sarcoma as a malignancy of lymphatic 
endothelial cells (3). In 1980s the prevalence of 
Kaposi’s sarcoma began to increase 
dramatically and became the most common 
malignancy in patients with Immunodeficiency 
disease (1,4). Hong and Lee in 2002 found that 
extracutenous or visceral Kaposi’s sarcoma 
lesions were more common in HIV infected 
patients rather than HIV-negative patients(2). 
Sung et al (4) in 1997 classified Kaposi’s 
sarcoma into four types: classic, African 
(endemic), iatrogenic or drug associated and 
Acquired Immunodeficiency Syndrome (AIDS)-
related Kaposi’s sarcoma. Classic Kaposi’s 
sarcoma usually follows an indolent disease of 
probably low malignant potential. In contrast, 
AIDS-Kaposi’s sarcoma is a fulminant disease 
that requires aggressive pharmacotherapy with 





S.M a male patient aged 68 who was referred 
from Ifakara, Morogoro region and admitted to 
surgical ward on 9th January 2003 with four 
months history of gradual onset of productive 
cough and haemoptysis. Sputum was purulent, 
not copious or foul smelling. The Cough was 
not related to posture but accompanied by 
episodes of haemoptysis, and localized dull ache 
on the lateral aspect of the left side of the chest. 
He had no fever, night sweats, and anorexia or 
weight loss. He did not respond to antibiotic 
therapy. He was married with eight children, all 
alive and well. He smoked three packets of 
cigarettes per day for about 40 years. He was a 
retired long distance truck driver. 
 
Physical examination revealed an elderly man of 
good nutritional status. He was not dyspnoeic, 
neither pale, nor febrile. He had no finger or toe 
clubbing. The cervical, axillary, or inguinal 
lymph nodes were not palpable. Pulse rate was 
80/minute, Blood pressure was 120/70. The 
respiratory rate was 18/minute, trachea was 
central and the chest was symmetrical in shape. 
There was a reduced chest expansion on the left 
hemithorax and dull percussion note over the 
left hemithorax with signs of consolidation. The 
right hemithorax was clinically normal. Other 
systems were examined and found to be normal. 
 
The provisional diagnosis of Bronchogenic 
Carcinoma was entertained. Investigations done 
included a chest X-ray that revealed left 
perihillar opacity with ill-defined margin 
(Fig.1). Haemoglobin was 12.0 g/dl, WBC: 
Normal count and distribution, ESR was 
80mm/hour Westergren method. Sputum for 
Acid Fast Bacilli (AFB) was negative, three 
times. Mid-morning sputum for cytology 
revealed no evidence of malignant cells ECG 
was within normal limits and abdominal 
ultrasound was normal. CT scan of the chest and 
upper abdomen revealed a soft tissue mass in 
the left upper lobe of the lung adherent to pleura 
with a small pleural effusion. No enlarged 
lymph nodes or bone involvement. No liver 
metastasis. Features were suggestive of a left 
lung tumour (Fig.2). 
 
Bronchoscopy was done and revealed a blunt 
carina, narrowed left main bronchus, with a 
tumour involving the left main bronchus close to 
its bifurcation into upper and lower lobe 
bronchi. Biopsies were taken for histological 
studies and results revealed features of Kaposi’s  
 




Figure 1. Chest X-ray 
 
 



























Figure 2. CT Scan
 









sarcoma. A review of the histology was 
requested and the tissue diagnosis confirmed the 
same. Double ELISA tests for HIV infection 
were negative. 
 
The Hospital Tumour board recommended 
palliative local (chest) radiotherapy to the 
patient. He was transferred to Ocean Road 
Cancer Institute on 13th February 2003 where he 
received five courses of 30Gy (300 rads) each 
over a period of five days with dramatic 
improvement on the symptoms. He was 
discharged home and reviewed on follow-up at 
the outpatient clinic three and six months later, 
and found to remain symptoms free with an 





Patients with primary classic Kaposi’s sarcoma 
appear to be at a higher risk of multiple 
malignancies5. Study by Iscovich et al5 in 1999 
when evaluating the risk of second neoplasms in 
1,016 HIV-negative patients with primary 
classic Kaposi’s sarcoma between 1961 to 1992 
in Jewish population found that 61 (6.0 %) 
patients developed second neoplasms. The 
commonest neoplasms were Non Hodgkin 

























In the same study it was found that 8.4% of 
patients with primary malignancies developed a 
secondary classic Kaposi’s sarcoma. The 
commonest primary malignancies being Non 
Hodgkin Lymphoma, Hodgkin Lymphoma, 
leukaemia and breast cancer (odds ratio were 
5.3, 7.5, 5.3 and 2.2 respectively).The case 
presented had no other malignancy found or any 
lesion elsewhere in his body suggestive of 
Kaposi’s sarcoma. 
 
Kaposi’s sarcoma of the lung of patients with 
HIV infection is often indistinguishable by 
clinical and radiologic criteria from 
opportunistic pneumonia though both may be 
present in the same patient6. The commonest 
clinical symptoms of Kaposi’s sarcoma of the 
lung includes dyspnoea, cough, occasionally 
haemoptysis and stridor7,8,9. Most frequent 
opportunistic chest infection seen in patients 
with AIDS are tuberculosis, bacterial 
pneumonia and pneumocystis carinii pneumonia 
(pcp), which clinically present with acute onset 
of fever, non-productive cough and dyspnoea10. 
The presented patient had no fever and was not 
dyspnoeic. 
 
Fibreoptic bronchoscopy and broncho-alveolar 
lavage and/or biopsy remain the standard 
investigation to differentiate between 
opportunistic pneumonia and pulmonary 
Kaposi’s sarcoma6,9. Hanson et al6 in 1987 
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performed 13 fibreoptic bronchoscopies in 
patients with thoracic manifestation of AIDS 
and identified Kaposi’s sarcoma in four (30%) 
bronchoscopic specimens. This yield was 
comparable to that obtained only by open lung 
biopsy procedures in previous reports. However, 
Daley et al11 in 1996 when evaluating the role of 
bronchoscopy and broncho-alveolar lavage in 
HIV positive patients with pulmonary 
manifestations found that the commonest 
opportunistic pulmonary infection was 
pulmonary tuberculosis (75 %), bacterial 
pneumonia (14 %), pcp (one patient) and 
Kaposi’s sarcoma (two patients-1%). It was 
concluded that bronchoscopy with broncho-
alveolar lavage added little to the diagnosis and 
should not be used for routine work-up in 
developing countries where tuberculosis is 
endemic. Similar study was done in Rwanda and 
revealed non-specific pneumonitis (38%), 
pulmonary tuberculosis (23%), cryptococcosis 
(13%), Kaposi’s sarcoma (9%), pcp (5%), 
undetermined cause (16%)12. 
 
Typically radiographic features of pulmonary 
Kaposi’s sarcoma (Fig.3) include bilateral 
involvement, ill-defined patchy opacities, hilar 
lymph node enlargement and pleural effusion1. 
Radiological features of pcp include bilateral 
patchy opacities with or without a cyst (Fig.4). 
 
The case presented had an ill-defined left peri-
hilar opacity on CXR which on CT scan 
examination (Figures 1 and 2) showed a left 
lung tumour involving pleura with small 
effusion on the same side. Ventilating rigid 
bronchoscopy revealed a tumour involving left 
main bronchus, left upper and left lower lobe 
bronchi. Biopsy was taken and histology results 
were confirmatory of Kaposi’s sarcoma. 
 
This was the second case of pulmonary Kaposi’s 
sarcoma in HIV-negative patients seen in 
Thoracic Surgical Unit over a 20-year period. 
Literature search found a report of only one case 
of pulmonary Kaposi’s sarcoma in an 
immunocompetent 32 years old heterosexual 
male. This patient was treated with vincristine 
and died of brain metastasis13. Kaposi’s sarcoma 
is common in HIV-infected patients and rare in 
HIV-negative or immunocompetent individuals. 
Pulmonary Kaposi’s sarcoma is rare in both 
HIV infected as well as immunocompetent 
persons. This is the main reason, which makes 
this case worth reporting. 
 
Systemic chemotherapy is said to be the most 
effective treatment for pulmonary Kaposi’s 
sarcoma although its efficacy may be limited by 
neutropenia14,15. The commonest 
chemotherapeutic agents used include 
Adriamycin, Bleomycin, Vincristine, Liposomal 
Daunorubicin and Doxorubicin and Paclitaxel 
(Taxol)14,15,16,17. Combination chemotherapy has 
been found to have a dramatic clinical and 
functional improvement than a single agent. It 
has been found that patients with AIDS-
associated pulmonary Kaposi’s sarcoma on 
chemotherapy and Highly Active Antiretroviral 
Therapy (HAART) increased survival18.  
 
Our patient was treated with local radiotherapy 
to the chest using 5 courses of 30 Gy, as he 
could not afford chemotherapy. Had a good 
response such that there was no more chest pain 
or haemoptysis. He was discharged home and 
seen at follow-up at three and six months 
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